a post-hoc evaluation of data from the HAWK and HARRIER trials
Autoren
Singer M, Khanani AM, Wolf A, Flores R, Chhablani J, B G, Clemens A, Gedif K, Liu X, Mulyukov Z, Querques G. Brolucizumab 12- and 16-week fixed dosing potential in neovascular AMD